SC
ALGS icon

SummitTX Capital’s Aligos Therapeutics ALGS Stock Holding History

SummitTX Capital’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
148,799
+9,375
+7% +$71.1K 0.03% 424
2025
Q4 		$1.3M Buy
+139,424
New +$1.32M 0.04% 371

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

SummitTX Capital's ALGS Position: Q1 2026 in Review

SummitTX Capital increased its Aligos Therapeutics (ALGS) stake by 6.7% in Q1 2026, buying an estimated $71.1K and bringing the position to 148,799 shares worth $1.11M. The position accounts for 0.03% of the portfolio, ranked #424.

SummitTX Capital first reported a position in ALGS in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.3M in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • SummitTX Capital held 148,799 shares of Aligos Therapeutics worth $1.11M as of Q1 2026.
  • SummitTX Capital bought 9,375 Aligos Therapeutics shares in Q1 2026, an estimated $71.1K.
  • Aligos Therapeutics made up 0.03% of SummitTX Capital's portfolio in Q1 2026, its #424 holding.
  • SummitTX Capital first reported a position in Aligos Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • SummitTX Capital's Aligos Therapeutics position peaked at $1.3M in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.